Salarius Pharmaceuticals, Inc.
SLRX
$0.83
-$0.02-2.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.70% | -9.89% | -8.56% | -13.23% | -30.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.84% | -23.18% | -38.55% | -55.53% | -71.65% |
| Operating Income | 2.84% | 23.18% | 38.55% | 55.53% | 71.65% |
| Income Before Tax | -0.22% | 21.05% | 37.54% | 55.55% | 72.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.22% | 21.05% | 37.54% | 55.55% | 72.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.22% | 21.05% | 37.54% | 55.55% | 72.31% |
| EBIT | 2.84% | 23.18% | 38.55% | 55.53% | 71.65% |
| EBITDA | 2.84% | 23.14% | 38.54% | 55.53% | 71.66% |
| EPS Basic | -215.94% | -- | -- | -- | -- |
| Normalized Basic EPS | 84.06% | -- | -- | -- | -- |
| EPS Diluted | -215.94% | -- | -- | -- | -- |
| Normalized Diluted EPS | 84.06% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 463.27% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 763.27% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |